LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP reminds investors in Omnicell, Inc. (“Omnicell” or the “Company”) (NASDAQ: OMCL) who purchased the Company’s between May 2, 2014 and March 2, 2015, inclusive (the “Class Period”) of the May 18, 2015 deadline, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Investors who purchased Omnicell shares during the Class Period are encouraged to contact Casey Sadler of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. If you are a member of the Class described above, you may move the Court no later than May 18, 2015 to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.
Omnicell provides automation and business information solutions designed to enable hospitals and long-term healthcare facilities to acquire, manage, dispense and administer medications and medical-surgical supplies. The Complaint alleges that defendants made false and misleading statements or failed to disclose material adverse facts, including the existence of a “side letter” arrangement with a Company customer for certain discounts and Company products that were to be provided at no cost, but which were not reflected in the final invoices paid by the customer; and, that the Company lacked adequate internal controls over financial reporting. On March 2, 2015, the Company announced the need to delay the filing of its annual report, because of the alleged “side letter” arrangement described above. Following disclosure of the above news, Omnicell shares fell $2.14 per share, or more than 6%, on March 3, 2015.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.